Braveheart Bio, Inc.

BRVE

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

19.38 0.24 −1.22%
Market cap
$1.8B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−28.7%
Net debt / EBITDA
1.3×
Payout ratio
—

Where the cash went Q3 FY2026, quarter to 30 September 2026

Free cash flow was −$24.4M: capital expenditures were more than operating cash flow. Cash fell by $1.5M. Lines the picture does not name came to −$386.2M. What is a cash flow statement?

Free cash flow
−$24.4M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
−$1.5M over the period
Where the cash went, in billions of dollars
Operating cash flow0.0
Free cash flow0.0
Shares issued, net+0.4
Other−0.4
Change in cash0.0
Operating cash flow, capex and free cash flow, three quartersOperating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, three quarters
Q1 FY26Q2 FY26Q3 FY26
Operating cash flow$0.0B$0.0B$0.0B
Capex$0.0B$0.0B$0.0B
Free cash flow$0.0B$0.0B$0.0B

Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Older periods Dec '25 Mar '26 Jun '26 Sep '26
Net Income

+3 more quarters

(6.45) (14.28) (14.99) (26.49)
Operating Cash Flow
(1.27) (5.19) (16.95) (24.37)
Investing cash flow
(0.83) (3.04) 0.01 (382.45)
Financing cash flow
23.74 (0.36) 59.20 405.28
Ending Cash
21.63 80.58 42.26 (1.54)

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 12 Nov 2026